Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	18,180	4,757	7,884	8,458	9,860	9,600
Short-Term Investments	62,648	74,450	56,515	37,671	18,675	23,084
Trading Asset Securities	8,464	8,247	5,933	19,239	29,299	22,203
Cash & Short-Term Investments	89,292	87,454	70,332	65,368	57,834	54,887
Cash Growth	20.20%	24.34%	7.59%	13.03%	5.37%	-7.32%
Accounts Receivable	4,195	3,991	4,595	4,566	4,664	4,835
Other Receivables	1,149	682.88	943.86	583.11	268.43	283.39
Receivables	5,610	4,976	5,740	5,330	5,216	5,557
Inventory	4,702	4,203	4,122	4,102	3,589	3,503
Prepaid Expenses	134.46	287.27	691.85	500.5	292.5	218.67
Other Current Assets	320.08	228.19	1,044	354.58	587.81	746.72
Total Current Assets	100,058	97,148	81,929	75,655	67,519	64,913
Property, Plant & Equipment	29,775	30,463	32,937	33,638	34,057	36,602
Long-Term Investments	501.94	501.94	501.94	3,786	8,427	2
Other Intangible Assets	1,576	1,606	1,599	1,793	1,536	1,802
Long-Term Accounts Receivable	0	0	0	0	0	0
Long-Term Deferred Tax Assets	216.96	216.96	182.29	449.3	751.56	1,395
Other Long-Term Assets	428.69	461.66	491.37	517.21	585.15	587.54
Total Assets	132,557	130,398	117,641	115,839	112,877	105,301
Accounts Payable	566.54	680.27	578.39	1,370	1,224	887.65
Accrued Expenses	606.21	481.51	489.15	443.91	470.95	496.32
Current Portion of Leases	612.71	650.28	621.14	600.78	402.89	658.65
Current Income Taxes Payable	1,688	1,404	-	1,038	814.73	-
Current Unearned Revenue	24.22	27.57	27.03	30.9	50.44	41.52
Other Current Liabilities	5,534	2,619	3,106	3,905	2,802	2,546
Total Current Liabilities	9,031	5,863	4,821	7,389	5,766	4,630
Long-Term Leases	246.64	366.66	934.17	357.79	423.49	686.44
Other Long-Term Liabilities	-	-	-	-	0	-
Total Liabilities	9,278	6,229	5,755	7,747	6,189	5,317
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760	12,760
Retained Earnings	129,254	130,264	118,217	114,993	109,894	102,696
Treasury Stock	-23,978	-23,978	-23,978	-23,978	-20,258	-20,258
Comprehensive Income & Other	542.82	422.69	186.4	-382.91	-408.42	86.97
Shareholders' Equity	123,279	124,168	111,885	108,092	106,687	99,985
Total Liabilities & Equity	132,557	130,398	117,641	115,839	112,877	105,301
Total Debt	859.34	1,017	1,555	958.57	826.38	1,345
Net Cash (Debt)	88,432	86,437	68,777	64,409	57,007	53,542
Net Cash Growth	21.43%	25.68%	6.78%	12.98%	6.47%	-8.16%
Net Cash Per Share	12921.34	12629.74	10049.37	9342.06	8061.43	7547.42
Filing Date Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.09
Working Capital	91,026	91,286	77,108	68,266	61,754	60,283
Book Value Per Share	18012.92	18142.94	16348.17	15793.91	15086.68	14094.07
Tangible Book Value	121,702	122,563	110,286	106,299	105,151	98,183
Tangible Book Value Per Share	17782.57	17908.31	16114.53	15531.88	14869.49	13840.05
Land	9,696	9,696	9,765	9,765	9,765	9,784
Buildings	20,123	19,675	19,537	13,349	13,854	14,389
Machinery	25,813	25,847	25,644	7,228	8,033	9,682
Construction In Progress	67.25	385.42	338.95	993.9	247.26	95

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.